Manufactured by Merck Serono, Saizen is produced by recombinant DNA technology from a mammalian cell line (mouse C127) that was modified by the addition of the human GH gene, resulting in an identical 191-amino acid sequence and structure.
Studies have shown that somatropin usage fails to produce athletic performance enhancement despite claims to the contrary.
More recently, Saizen has been used in IVF protocols by a few physicians for female patients undergoing infertility treatment in an attempt to increase the number and quality of oocytes retrieved.
It affects: Saizen usage should be performed under the regular guidance of a physician who is experienced in the diagnosis and management of growth hormone deficiency.
Because human growth hormone may induce a state of insulin resistance, patients should be observed for evidence of glucose intolerance.